{"slug":"humanin","seoKey":"humanin","displayName":"Humanin","codes":["HN","HNG","HNGF6A"],"synonyms":["Humanin (human)","Protein Humanin (human)","1-24-Protein humanin (human)","formyl humanin","fHN","Humanin trifluoroacetate","MT-RNR2-encoded peptide","mitochondria-derived peptide humanin"],"legalClass":"research_chemical","identifiers":{"cas":"330936-69-1","pubchemCid":16131438,"unii":"H975EUX36G","inchikey":"DPEUWKZJZIPZKE-OFANTOPUSA-N","chemblId":"CHEMBL4447799","wikidataQid":"Q27077999","formula":"C119H204N34O32S2","molecularWeight":2687.2,"sequence":"MAPRGFSCLLLLTSEIDLPVKRRA"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved: no approved medicinal product, no component of one, and no listing among the bulk drug substances nominated for compounding. Four independent queries returned nothing on 2026-09-20, each with a working control query: the agency's drug label database returned NOT_FOUND, its approved-products database returned NOT_FOUND, the national labelling archive returned no record, and the substance does not appear in the full text of the compounding nomination list. What does exist is a substance registry entry with the identifier H975EUX36G carrying the internal status 'approved'. That status describes the review state of the data record only; it is issued for any identifiable substance, including environmental chemicals, and it is not a marketing authorisation. The adverse event database holds a single serious report, received on 2024-09-12 and filed by a physician, describing a 56-year-old man after a 5 mg subcutaneous self-injection reconstituted with distilled water, with a picture of botulism; such reports are suspicions without proof of causation, and it is not established that the injected material contained the substance at all.","source":"https://api.fda.gov/drug/label.json?search=humanin"},{"market":"EU","status":"not_approved","note":"Not approved: no centralised marketing authorisation, no assessment report and no withdrawn application could be found. Honest limitation: the agency's own search could not be queried from the working environment on 2026-09-20 — the full-text search returned HTTP 401 and the medicines page returned only a JavaScript shell with no readable result list. This negative finding is therefore derived rather than independently confirmed by machine: there is no clinical development anywhere in the world, and the chemical database entry carries no development phase and no approval date.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=humanin"},{"market":"DE","status":"not_approved","note":"Not approved: neither a centralised EU authorisation nor a national one exists, so every injectable preparation is an unauthorised medicinal product. The substance is also not named in the annex to the anti-doping act: the full text was checked on 2026-09-20 and contains no entry, which distinguishes it from a number of other peptides traded in the same channel. The criminal provisions of that act therefore do not apply to it, while the general rules on unauthorised medicines do.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Not approved: no authorised medicine carries this substance. Honest limitation: the regulator's product index returned only a JavaScript shell when queried on 2026-09-20, so this negative finding is not independently confirmed by machine. Unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012.","source":"https://products.mhra.gov.uk/search/?search=humanin"},{"market":"AU","status":"not_approved","note":"Not approved, and — unlike several other traded peptides — not named in the Poisons Standard either: the full text of the June 2026 instrument was searched locally on 2026-09-20 with a working control search, and the substance appears in no schedule and not in Appendix D. Honest limitation: the register of therapeutic goods itself was unreachable on that date (the request returned no response at all), so the absence of a registered product is derived rather than independently confirmed. Preparations of this kind are handled as unapproved therapeutic goods.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query of the drug product database returned an empty result on 2026-09-20, and a second query on a variant spelling returned the same. A control query for a comparable substance returned matches in the same call, so the negative finding is sound.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=humanin"},{"market":"CH","status":"not_approved","note":"Not approved: no authorised human medicine carries this substance. Honest limitation: the authority's search returned HTTP 404 on 2026-09-20 and the authorisation register could not be queried by machine, so this negative finding is derived rather than independently confirmed. Beyond the seven markets listed here, no product could be found for Russia, China or Japan either — but no registry query was run for those three, so their absence is non-findability, not a checked negative finding; the residual doubt is largest for Japan, where the substance was discovered in 2001.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"observational","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT03431844","name":"Humanin isoforms in cardiac muscle and plasma and major complications after cardiac surgery (observational cohort; humanin measured, not given)","phase":"Observational","n":106,"status":"COMPLETED"},{"nct":"NCT06105229","name":"Clinical value of plasma humanin in acute kidney injury (observational; humanin concentration as an endpoint, not an intervention)","phase":"Observational","n":60,"status":"UNKNOWN"},{"nct":"NCT06125249","name":"Humanin for early diagnosis and short-term prognosis of acute kidney injury after heart surgery (observational; humanin measured, not given)","phase":"Observational","n":60,"status":"UNKNOWN"},{"nct":"NCT04104958","name":"IVF outcome in polycystic ovary syndrome (case-control; humanin expression measured at mRNA level, no substance administered)","phase":"Observational","n":100,"status":"UNKNOWN"},{"nct":"NCT05506228","name":"Muscle biopsies in cerebral palsy taken during orthopaedic surgery (case-control; humanin a side mention among muscle metabolism measures)","phase":"Observational","n":150,"status":"RECRUITING"},{"nct":"NCT07678073","name":"Anaesthesia technique and ferroptosis, humanin and MOTS-c levels in renal transplantation (interventions are the two anaesthesia methods; humanin is a primary-endpoint marker, not given)","phase":"N/A","n":68,"status":"RECRUITING"},{"nct":"NCT07438002","name":"High-intensity physical exercise in dialysis patients (interventions are exercise and control; humanin appears only in the study description, endpoints are walking speed and strength)","phase":"N/A","n":50,"status":"RECRUITING"}],"sameAs":["https://www.wikidata.org/wiki/Q27077999","https://pubchem.ncbi.nlm.nih.gov/compound/16131438","https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4447799/"],"lastVerified":"2026-09-20","version":"1.0","published":true,"locale":"en","title":"Humanin: what the studies show, status and safety","summary":"Humanin is a short peptide of 24 building blocks that the body makes itself, from a gene that sits inside the mitochondria rather than in the cell nucleus. It has been researched since 2001, but in those 25 years no person has ever been given a dose in a study. Every human finding is a measurement of the peptide in blood or tissue, never a treatment. No country has approved it, and the one serious report on record concerns a contaminated injection rather than the substance itself.","updated":"2026-09-20","url":"https://mypep.app/peptides/humanin"}